Hormonal Therapy is treatment that adds, blocks, or removes hormones. For certain conditions (such as diabetes or menopause), hormones are given to adjust low hormone levels. To slow or stop the growth of certain cancers (such as prostate and breast cancer), synthetic hormones or other drugs may be given to block the body’s natural hormones. Sometimes surgery is needed to remove the gland that makes a certain hormone. Also called endocrine therapy, hormone therapy, and hormone treatment.
Researchers have managed to grow human, testosterone-producing cells, which could lead to improved treatment options for low testosterone levels.
October is Breast Cancer Awareness Month, an annual campaign to raise awareness about the potentially-fatal disease. Breast cancer is known as an illness that affects mostly women, but about 1 percent of all breast cancers affect men, too.
A new PARP-inhibitor has been shown to significantly delayed cancer progression among patients with prostate cancer who had cancer cells with faulty DNA repair genes.
A study led by UCLA researchers found that adding ribociclib, a targeted therapy drug, to standard hormone therapy has been shown to significantly improve overall survival in postmenopausal women with advanced hormone-receptor positive/HER2- breast cancer, one of the most common forms of the disease.
Breast cancer is one of the most aggressive types of cancers in the world. It is the commonest cause of cancer death in women worldwide, and it represented about 12 percent of all new cancer cases in 2012. Current predictions and statistics suggest that both worldwide incidence of breast cancer and related mortality are on the rise. Globally, breast cancer now represents one in four of all cancers in women.
Electromagnetic fields might help prevent some breast cancers from spreading to other parts of the body, new research has found.
A new portable device that utilizes artificial intelligence (AI) and biosensors can rapidly detect if cancer cells thrive after chemotherapy treatment.
There have been studies and anecdotal reports about worsening of sleep quality and increasing fatigue among women who are near menopause or have reached menopause.
Pelvic pain associated with endometriosis often becomes chronic and can persist (or recur) following surgical and hormonal interventions.
Adding the targeted therapy ribociclib to hormone therapy significantly improved overall survival (OS) in premenopausal patients with advanced hormone receptor-positive (HR+) breast cancer, according to results of the MONALEESA-7 Phase III clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.
Enzalutamide, an oral androgen receptor inhibitor, can improve outcomes for men with metastatic hormone-sensitive prostate cancer, according to a large study presented by Christopher Sweeney, MBBS of Dana-Farber Cancer Institute's Lank Center for Genitourinary Oncology, during the American Society of Clinical Oncology Annual Meeting.
Nearly all women who have been treated for non-metastatic breast cancer suffer from health problems after primary treatment.
Nearly ninety per cent of all cancer patient deaths are due to metastasis. A study from Uppsala University shows that a process that allows the cells to metastasize is aided by the synthesis of new ribosomes, the cell components in which proteins are produced.
Researchers at Karolinska Institutet in Sweden have identified blood-based biomarkers that may determine which patients will benefit from continued hormonal therapy for advanced prostate cancer.
The American Society for Radiation Oncology and the American Urological Association today announced updates to their joint clinical guideline on adjuvant and salvage radiotherapy after prostatectomy in patients with and without evidence of prostate cancer recurrence to include new published research related to adjuvant radiotherapy.
A breast cancer test has been found that helps doctors make treatment decisions for some breast cancer patients, following research carried out at Queen Mary University of London and funded by Cancer Research UK.
The U.S. Food and Drug Administration today is extending the indication of Ibrance (palbociclib) capsules in combination with specific endocrine therapies for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in male patients.
Two years after diagnosis, breast cancer survivors have four times more positive than negative thoughts about changes they experienced because of their illness, a new study found.
Some patients with metastatic prostate cancer respond to a combination of immune checkpoint inhibitors after hormonal therapy and chemotherapy have failed, according to early results from a clinical trial led by investigators at The University of Texas MD Anderson Cancer Center presented today at the American Society of Clinical Oncology Genitourinary Cancers Symposium in San Francisco.
Atypical ductal hyperplasia is a breast lesion associated with a four- to five-fold increase in the risk of breast cancer.